PTLA: More interesting IPO than many other recent IPOs to me. I am skeptical of Betrixaban too, everyone should with its history. Even if I weren't, it would still be too little too late. PRT4445, on the other hand, could be a real important product. There isn't much clinical data yet, worth watching closely. Syk and JAK are pretty much validated targets to me, thus depends on specific drug. They have a lot of cash too, profitable for the past two years, very rare. I haven't read their filing yet. It would be interesting to see how the market value the company.
Market Data 
Markets 
AI
